Alla Tsirlina
Family Medicine · Brooklyn, NYNPI 1962423020
Payments from drug & device makers
Across 442 payments — averaging $39.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Amgen$3K
- GSK$2K
- Amarin Pharma, Inc.$1000
- AstraZeneca$891
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$828
- plus $5K from 18 others
What the payments were for
- Travel & lodging$240%
- Food & beverage$17,247100%
- Education$380%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 86 | $4,158 |
| Amgen | 52 | $3,111 |
| GSK | 51 | $2,212 |
| Amarin Pharma, Inc. | 23 | $1,000 |
| AstraZeneca | 29 | $891 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 32 | $828 |
| Bayer | 19 | $714 |
| Boehringer Ingelheim | 16 | $437 |
| Lilly USA, LLC | 17 | $395 |
| Novo Nordisk | 11 | $391 |
| Novartis | 14 | $346 |
| Kowa Pharmaceuticals America, Inc. | 17 | $343 |
| Regeneron Healthcare Solutions, Inc. | 6 | $329 |
| E.r. Squibb & Sons, L.L.C. | 5 | $305 |
| Pfizer | 7 | $303 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $290 |
| Sanofi-aventis U.S. LLC | 2 | $241 |
| Axsome Therapeutics, Inc. | 4 | $213 |
| Nestle Healthcare Nutrition Inc. | 13 | $207 |
| Arbor Pharmaceuticals, Inc. | 10 | $193 |
| Teva Pharmaceuticals USA, Inc. | 1 | $125 |
| Merck | 7 | $116 |
| Azurity Pharmaceuticals, Inc. | 5 | $93 |
| Ironwood Pharmaceuticals, Inc | 3 | $69 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,310 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $6,768 |
| VascepaIcosapent Ethyl | 19 | $6,413 |
| Diclofenac Sodium | 23 | $3,675 |
| Dexlansoprazole DrDexlansoprazole | 14 | $3,117 |
| Rosuvastatin Calcium | 23 | $88 |
| Atorvastatin Calcium | 20 | $42 |
| Losartan Potassium | 13 | $37 |
| Amlodipine Besylate | 25 | $30 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $303 | $6,76811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.
Other family medicine in Brooklyn
- Michael YuryevBrooklyn$589K
- Matthew SpitzerBrooklyn$469K
- Walford LindoBrooklyn$104K
- Fu Fu HeBrooklyn$101K
- Jonathan ChangBrooklyn$66K
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.